Criteria for monitoring tests were described: validity, responsiveness, detectability of long-term change, and practicality

被引:10
作者
Bell, Katy J. L. [1 ,2 ]
Glasziou, Paul P. [1 ]
Hayen, Andrew [3 ]
Irwig, Les [2 ]
机构
[1] Bond Univ, CREBP, Gold Coast, Qld 4229, Australia
[2] Univ Sydney, Sch Publ Hlth, Screening & Diagnost Test Evaluat Program STEP, Sydney, NSW 2006, Australia
[3] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia
基金
英国医学研究理事会;
关键词
Chronic disease; Disease management; Diagnostic tests; Biological markers; Reproducibility of results; Statistical models; LOWER BLOOD-PRESSURE; RHEUMATOID-ARTHRITIS; MEASUREMENT ERROR; CHOLESTEROL; DISEASE; RELIABILITY; MARKERS; EVENTS; TRIAL; RISK;
D O I
10.1016/j.jclinepi.2013.07.015
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To describe how evidence from trials and cohort studies may be used to guide choice of test for monitoring patients with chronic disease. Study Design and Setting: Exploration of potential criteria for choosing the best monitoring test. Criteria are defined and options for assessment measures for test performance on each criterion discussed. Results: Monitoring in clinical practice occurs in three main phases: before treatment, response to treatment, and long-term monitoring. Four important criteria may be used to choose the best test for monitoring a patient in each of these phases. Clinical validity describes the ability of the test to predict the clinically relevant outcome that we are trying to control or prevent. Responsiveness describes how much the test changes in response to an intervention relative to background random variation. Detectability of long-term change describes the size of changes in the test over the long term relative to background random variation. Practicality describes the ease of use, invasiveness, and cost of the test. Test performance generally requires longitudinal data from trial and/or cohort studies using statistical methods such as those discussed. Conclusion: Four specific criteria can help clinicians inform evidence-based decisions on which monitoring test to use. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:152 / 159
页数:8
相关论文
共 29 条
[1]   Use of randomised trials to decide when to monitor response to new treatment [J].
Bell, Katy J. L. ;
Irwig, Les ;
Craig, Jonathan C. ;
Macaskill, Petra .
BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7640) :361-365
[2]   The potential value of monitoring bone turnover markers among women on alendronate [J].
Bell, Katy J. L. ;
Hayen, Andrew ;
Irwig, Les ;
Hochberg, Marc C. ;
Ensrud, Kristine E. ;
Cummings, Steven R. ;
Bauer, Douglas C. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (01) :195-201
[3]   Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials [J].
Bell, Katy J. L. ;
Hayen, Andrew ;
Macaskill, Petra ;
Craig, Jonathan C. ;
Neal, Bruce C. ;
Fox, Kim M. ;
Remme, Willem J. ;
Asselbergs, Folkert W. ;
van Gilst, Wiek H. ;
MacMahon, Stephen ;
Remuzzi, Giuseppe ;
Ruggenenti, Piero ;
Teo, Koon K. ;
Irwig, Les .
HYPERTENSION, 2010, 56 (03) :533-U429
[4]   Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers [J].
Bell, Katy J. L. ;
Irwig, Les ;
March, Lyn M. ;
Hayen, Andrew ;
Macaskill, Petra ;
Craig, Jonathan C. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (01) :99-105
[5]   Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data [J].
Bell, Katy J. L. ;
Hayen, Andrew ;
Macaskill, Petra ;
Irwig, Les ;
Craig, Jonathan C. ;
Ensrud, Kristine ;
Bauer, Douglas C. .
BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 :1553
[6]   Mixed models showed no need for initial response monitoring after starting antihypertensive therapy [J].
Bell, Katy J. L. ;
Hayen, Andrew ;
Macaskill, Petra ;
Craig, Jonathan C. ;
Neal, Bruce C. ;
Irwig, Les .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2009, 62 (06) :650-659
[7]   Statistics notes: Measurement error proportional to the mean .23. [J].
Bland, JM ;
Altman, DG .
BRITISH MEDICAL JOURNAL, 1996, 313 (7049) :106-106
[8]   Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis [J].
Boekholdt, S. Matthijs ;
Arsenault, Benoit J. ;
Mora, Samia ;
Pedersen, Terje R. ;
LaRosa, John C. ;
Nestel, Paul J. ;
Simes, R. John ;
Durrington, Paul ;
Hitman, Graham A. ;
Welch, K. M. A. ;
DeMicco, David A. ;
Zwinderman, Aeilko H. ;
Clearfield, Michael B. ;
Downs, John R. ;
Tonkin, Andrew M. ;
Colhoun, Helen M. ;
Gotto, Antonio M., Jr. ;
Ridker, Paul M. ;
Kastelein, John J. P. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (12) :1302-1309
[9]   Diagnosis - Comparative accuracy: assessing new tests against existing diagnostic pathways [J].
Bossuyt, PM ;
Irwig, L ;
Craig, J ;
Glasziou, P .
BRITISH MEDICAL JOURNAL, 2006, 332 (7549) :1089-1092
[10]   General cardiovascular risk profile for use in primary care - The Framingham Heart Study [J].
D'Agostino, Ralph B. ;
Vasan, Ramachandran S. ;
Pencina, Michael J. ;
Wolf, Philip A. ;
Cobain, Mark ;
Massaro, Joseph M. ;
Kannel, William B. .
CIRCULATION, 2008, 117 (06) :743-753